valentina mastrofilippo

Dr. valentina mastrofilippo

IRCCS Azienda Unità Sanitaria Locale di Reggio Emilia
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EBElena Bolletta
Elena Bolletta
DIDanilo Iannetta
Danilo Iannetta
VMvalentina mastrofilippo
valentina mastrofilippo
Luca De SimoneLuca De Simone
Luca De Simone
FGFabrizio Gozzi
Fabrizio Gozzi
Luca CiminoLuca Cimino
Luca Cimino
Coronavirus disease 2019 (COVID-19) vaccines can cause transient local and systemic post-vaccination reactions. The aim of this study was to report uveitis and other ocular complications following COVID-19 vaccination. The study included 42 eyes of 34 patients (20 females, 14 males), with a mean age of 49.8 years (range 18–83 years). The cases reported were three herpetic keratitis, two anterior scleritis, five anterior uveitis (AU), three toxoplasma retinochoroiditis, two Vogt-Koyanagi-Harada (VKH) disease reactivations, two pars planitis, two retinal vasculitis, one bilateral panuveitis in new-onset Behçet’s disease, three multiple evanescent white dot syndromes (MEWDS), one acute macular neuroretinopathy (AMN), five retinal vein occlusions (RVO), one non-arteritic ischemic optic neuropathy (NAION), three activations of quiescent choroidal neovascularization (CNV) secondary to myopia or uveitis, and one central serous chorioretinopathy (CSCR). Mean time between vaccination and ocular complication onset was 9.4 days (range 1–30 days). Twenty-three cases occurred after Pfizer-BioNTech vaccination (BNT162b2 mRNA), 7 after Oxford-AstraZeneca vaccine (ChAdOx1 nCoV-19), 3 after ModernaTX vaccination (mRNA-1273), and 1 after Janssen Johnson & Johnson vaccine (Ad26.COV2). Uveitis and other ocular complications may develop after the administration of COVID-19 vaccine.

1 November 2017 in Ophthalmology
Verified
Journal Article
Closed access
AIAlessandro Invernizzi
Alessandro Invernizzi
SMSylvia Marchi
Sylvia Marchi
RARaffaella Aldigeri
Raffaella Aldigeri
VMvalentina mastrofilippo
valentina mastrofilippo
FVFabiana Viscogliosi
Fabiana Viscogliosi
Luca CiminoLuca Cimino
Luca Cimino

21 May 2018 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
MCMarco Coassin
Marco Coassin
VMvalentina mastrofilippo
valentina mastrofilippo
JSJay M. Stewart
Jay M. Stewart
AFAndrea Fanti
Andrea Fanti
MBMatteo Belpoliti
Matteo Belpoliti
LFLuigi Fontana
Luigi Fontana

7 October 2020 in Journal of Glaucoma
Verified
Journal Article
Closed access
Luigi FontanaLuigi Fontana
Luigi Fontana
MMMichele De Maria
Michele De Maria
ACAlice Caristia
Alice Caristia
VMvalentina mastrofilippo
valentina mastrofilippo
LBLuca Braglia
Luca Braglia
GSGiuliano Pio Scarale
Giuliano Pio Scarale
Précis: Trabeculectomy (TRAB) lowers the intraocular pressure (IOP) more than gonioscopy-assisted transluminal trabeculotomy (GATT) at 18 months, with a reduction in IOP of 30% or more and a significant reduction in the number of glaucoma medications compared with baseline. Purpose: To compare the IOP-lowering efficacy of GATT with mitomycin-C augmented TRAB in patients with uncontrolled open-angle glaucoma. Methods: Single-center, retrospective, comparative cohort study. One hundred ten consecutive patients (110 eyes) underwent GATT (n=61) or TRAB (n=49). The primary outcome measure was IOP reduction, defined as a percentage decrease ≥30% and absolute IOP≤18 mm Hg at 18 months with (qualified) or without (complete) medications. Secondary outcomes were visual field change, number of glaucoma medications, complications, and reintervention. Results: The mean±SD baseline IOP was 30.04±7.5 and 27.59±4.70 (P=0.072) with the mean number of medications of 3.08±0.73 and 2.92±0.91 (P=0.310) in TRAB and GATT, respectively. At 18 months, the mean±SD IOP was 15.26±3.47 mm Hg and 12.48±4.58 mm Hg after GATT and TRAB, respectively (P=0.002). The percentage of IOP lowering from baseline was 56.05±17.72 after TRAB and 42.04±15.56 after GATT (P<0.001). Percentages of complete and qualified success were 59% and 27% after TRAB and 46% and 31% after GATT (P=0.353). No change in visual field loss was observed in both groups. The mean reduction in medications was 2.3±1.4 and 2.1±1.5 in TRAB and GATT, respectively (P=0.493). The most frequent complication after TRAB was hypotony and after GATT hyphema. Reintervention occurred in 8.2% of cases after TRAB and in 14.8% after GATT (P=0.341). Conclusions: IOP lowering was greater after TRAB than after GATT at 18 months with a significant reduction in the number of medications after both procedures. Complications and reintervention occurred equally in both groups but differed in type.

1 December 2017 in Medicine
Verified
Journal Article
Open access
PDF file
VMVincenzo Dario Mandato
Vincenzo Dario Mandato
RVRiccardo Valli
Riccardo Valli
VMvalentina mastrofilippo
valentina mastrofilippo
ABAlessandra Bisagni
Alessandra Bisagni
LALorenzo Aguzzoli
Lorenzo Aguzzoli
GSGiovanni Battista La Sala
Giovanni Battista La Sala
Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal neoplasm composed of spindled to epithelioid cells with prominent myxoid stroma and inflammatory infiltrate. It has a low but definite malignant potential. However, its management has never been standardized. We present the first case of uterine IMT laparoscopically treated. Moreover, we reviewed the English literature regarding uterine IMT published between 1987 and June 2017. A total of 72 cases of uterine IMT were included. Clinical and pathological characteristics, treatments and outcomes were recorded. A total laparoscopic hysterectomy with opportunistic bilateral salpingectomy was performed. Patient is free of disease at 6 months of follow-up. Uterine IMT may be identified by anaplastic lymphoma kinase overexpression, its prognosis is usually good, complete excision seems to be effective to avoid relapse and mini invasive surgery seems to be effective and safe to treat uterine IMT. However, considering the age of women affected by disease, conservative management, or medical therapy could be taken in account to avoid surgical injuries and to preserve fertility.

4 June 2021 in Medicine
Verified
Journal Article
Open access
VMVincenzo Dario Mandato
Vincenzo Dario Mandato
VMvalentina mastrofilippo
valentina mastrofilippo
APAndrea Palicelli
Andrea Palicelli
MSMonica Silvotti
Monica Silvotti
SSSilvia Serra
Silvia Serra
LALorenzo Aguzzoli
Lorenzo Aguzzoli
Rationale: Endometrial cancer (EC) is the most common gynecological malignancy in developed countries. It is usually diagnosed at early-stage and presents a favorable prognosis. Conversely, advanced or recurrent disease shows poor outcome. Most recurrences occur within 2 years postoperatively, typically in pelvic and para-aortic lymph nodes, vagina, peritoneum, and lungs. Vulvar metastasis (VM) is indeed anecdotal probably because of the different regional lymphatic drainage from corpus uteri. Patient concerns: A 3 cm, reddish, bleeding lesion of the posterior commissura/right labia was found in a 74-year-old woman treated with radical hysterectomy, surgical staging, and adjuvant radiotherapy 1 year before for a grade 2 endometrioid type, International Federation of Gynecology and Obstetrics Stage IB. Vulvar biopsy confirmed the EC recurrence. Pelvic magnetic resonance imaging and positron emission tomography excluded other metastases so VM was radically resected. Diagnosis: Postoperative histopathology confirmed the diagnosis of grade 2 EC VM. Interventions: A radical excision of VM was performed. Outcomes: Patient died from a severe sepsis 27 months after first surgery. Lessons: Vulvar metastases can show different appearance, occurring as single or diffuse lesions on healthy or injured skin. The surgical approach seems not to influence the metastatic risk, but tumor seeding and vaginal injuries should be avoided. Whether isolated or associated with recurrence in other locations, vulvar metastases imply poor prognosis despite radical treatment. Therefore, any suspected vulvar lesion arisen during EC follow-up should be biopsied and monitored closely, despite that the vulva represents an unusual metastatic site.